Online inquiry

IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7311MR)

This product GTTS-WQ7311MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FGFR2 gene. The antibody can be applied in Gastric Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000141.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2263
UniProt ID P21802
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7311MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3311MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ASN-100
GTTS-WQ10833MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA M7824
GTTS-WQ3028MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ8565MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ5225MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CB 2679d
GTTS-WQ10043MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ15625MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA VAY-736
GTTS-WQ12827MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ONC-005
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW